Wolfgang Jacob

6PUBLICATIONS
46CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 30, 2026
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

|Sep 16, 2026
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

|Jun 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin

|Aug 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff

|Jan 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell

Pageof 1

Frequent Collaborators

2 joint publications

Salomon Manier

2 joint publications

Simon J Harrison

2 joint publications

Paolo Corradini

2 joint publications

Carmelo Carlo-Stella